Company

About

DICE-CRO

DICE-CRO

't Hofveld, Groot-Bijgaarden, Flemish Region 1702, BE

Our mission is to enhance access to medical treatment by delivering excellence in the design and execution of clinical trials. DICE is a Contract Research Organization with over 30 years of experience in the execution of clinical trials. We have assisted in the execution of Phase I-IV studies and supported in the defense at EMA and FDA with clients from across the globe. We have expertise in an array of therapeutic areas and experience in the development of different medical technologies. DICE offers a variety of services including: Clinical Study Design, Clinical Data Management, Biostatistical Analysis, Medical Writing, Central Imaging Review, and Medical Monitoring. Our knowledgeable and dedicated team of experts have a drive and curiosity that encourages them to take on projects as if they were their own. At DICE, your success is our own success. For more information, visit www.dice-cro.com

Ncardia (Evotec)

Ncardia (Evotec)

Gosselies, Belgium

Ncardia's hiPSC products portfolio encompasses a broad panel of cardiovascular and neural cells. In addition, the company delivers the Cardioplateā„¢ product line of quality-controlled ready-to-use assay plates.

P95

P95

Rue Edith Cavell 66/3, 66, Uccle, 1180, BE

4Clinics is a Contract Research Organization (CRO) providing Data management, Biostatistics, Scientific Writing, Regulatory Affairs and Clinical Operations services for clinical and epidemiological studies with a particular expertise in vaccines, immunology, immuno-oncology and medical devices. 4Clinics serves pharmaceutical, biotechnology and medical devices companies as well as NGOs, hospitals and researchers with tailor-made services including remote biometry and medical writing platforms. 4Clinics has offices in Belgium, France and Morocco and has a global coverage. For more information, please visit www.4Clinics.com

reMYND

reMYND

Leuven, Belgium

reMYND NV is a dynamic biotech company located in Leuven (Belgium) that actively drives R&D in the field of protein misfolding diseases, among others Alzheimer's disease (AD) and Parkinson's disease (PD). The company consists of two independently managed units. The Drug Discovery and Development Unit focuses on disease-modifying treatments for among others AD and PD (counteracting TAU and aSyn toxicity, respectively). The Contract Research Unit offers extensive experience in the testing of experimental Alzheimer therapies in its unique and proprietary transgenic mouse models. For more information please visit www.remynd.com Alternatively, please contact Koen De Witte (Managing Director - pipeline@remynd.com) to hear more about reMYND's pipeline or Bart Roucourt (Manager Contact Research - cro@remynd.com) to get more information on reMYND's Contract Research Offering.